Diagnosing Lung Cancers through Examination of Micro-RNA Biomarkers in Blood, Plasma, Serum and Sputum: A Review and Summary of Current Literature

Gyoba, Jennifer; Shan, Shubham; Roa, Wilson; Bédard, Éric

doi:10.3390/ijms17040494

Cited by 59 publications

(48 citation statements)

References 48 publications

(173 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of micro-RNAs (miRs) have recently been implicated in lung cancer and mTOR regulation. 42,43 In osteosarcoma cells, rapamycin induces miR-34b, which improves sensitivity to anticancer drugs. Interestingly, decreased expression of miR-34b was detected in samples of chemoresistant osteosarcoma patients when compared to chemosensitive samples.…”

Section: The Mtor Signaling Pathwaymentioning

confidence: 99%

Targeting the Mammalian Target of Rapamycin in Lung Cancer

Vicary

Roman

2016

The American Journal of the Medical Sciences

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death worldwide. Despite advances in its prevention and management, the prognosis of patients with lung cancer remains poor. Therefore, much attention is being given to factors that contribute to the development of this disease, the mechanisms that drive oncogenesis and tumor progression and the search for novel targets that could lead to the development of more effective treatments. One cellular pathway implicated in lung cancer development and progression is that of the mammalian target of rapamycin. Studies involving human tissues have linked lung cancer with abnormalities in this pathway. Furthermore, studies in vitro and in vivo using animal models of lung cancer reveal that targeting this pathway might represent an effective means of treating this disease. As a result, there is significant effort invested in the development of drugs targeting mammalian target of rapamycin and related pathways in the clinical setting.

show abstract

Section: The Mtor Signaling Pathwaymentioning

confidence: 99%

Targeting the Mammalian Target of Rapamycin in Lung Cancer

Vicary

Roman

2016

The American Journal of the Medical Sciences

View full text Add to dashboard Cite

show abstract

“…Lung cancer remains the leading cause of cancer-related death across the globe with a 5-year survival rate of less than 15% [1,2]. As the most common lung cancer, non-small cell lung cancer (NSCLC) poses a major threat to public health.…”

Section: Introductionmentioning

confidence: 99%

“…Despite substantial advances in diagnostic and therapeutic approaches, the overall survival for NSCLC patients still remains poor [3]. One main impediment for the treatment of NSCLC is that most patients are diagnosed at advanced or metastatic stages (stage III/IV) when the prognosis is poor and therapeutic options are limited [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Design, synthesis and in vitro evaluation of new thiosemicarbazone derivatives as potential anticancer agents

Sever¹,

Çiftçi²,

Özdemır³

et al. 2018

jrp

View full text Add to dashboard Cite

Thiosemicarbazones play a pivotal role as potential therapeutic agents for the management of lung cancer. 4-(4-Cyanophenyl)-1-[(5-arylfuran-2-yl)methylene]thiosemicarbazides (1-10) were obtained via the reaction of 4-(4cyanophenyl)thiosemicarbazide with 5-arylfurfurals. MTT assay was performed to assess their cytotoxic effects on A549 human lung adenocarcinoma and L929 mouse fibroblast cell lines. Compounds 1, 5, 6 and 7 were identified as the most effective anticancer agents on A549 cell line with IC50 values of 12.75±0.35 µg/mL, 4.30±0.61 µg/mL, 5.50±2.12 µg/mL and 5.90±0.57 µg/mL, respectively compared to cisplatin (IC50= 12.00±0.71 µg/mL). The IC50 values of these compounds for L929 cell line were higher than their IC50 values for A549 cell line indicating that their anticancer effects were selective. The apoptotic effects of these compounds were also analyzed based on Annexin V-PI binding capacities in flow cytometry. According to flow cytometric analyses, the early apoptotic effects of compounds 1, 5, 6 and 7 on A549 cell line were determined as 4.7, 5.1, 7.3 and 5.1%, whereas their late apoptotic effects were determined as 3.7, 2.0, 4.9 and 3.3%, respectively. Compound 6 showed more apoptotic activity than compounds 1, 5 and 7. According to these findings, compounds 5 and 6 stand out as promising anticancer agents for further in vitro and in vivo studies.

show abstract

“…Lung cancer has always been one of major malignancies worldwide, with an estimated 20.9 million new cases and 17.6 million people die from lung cancer in the GLOBOCAN database (1). Lung cancer includes both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), but the latter accounts for more than 80% of lung cancer cases (2). Lung cancer patients are usually diagnosed at advanced stages, and usually more than 60% of patients are at stage or before treatment (3).Thus, despite there is progress in cancer treatment, the prognosis of NSCLC remains poor and the 5-year survival rate of lung cancer is less than 20%, the survival rate of this disease has remained virtually unchanged (4,5).…”

Section: Introductionmentioning

confidence: 99%

Low miR-1231 expression predicts poor prognosis in non-small cell lung cancer and accelerates cell proliferation, migration and invasion

Zhu

Zhang

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background MicroRNAs (miRNAs) have been confirmed to be involved in the tumor progression of various cancer types. This study aimed to assess the prognostic significance and biological function of miR-1231 in patients with non-small cell lung cancer (NSCLC). Methods The expression of miR-1231 was estimated using quantitative real-time polymerase chain reaction (qRT-PCR). Kaplan-Meier survival curves and Cox regression analysis were used to evaluate the prognosis value of miR-1231 in patients with NSCLC. Cell experiments were performed to assess the biological function of miR-1231 in the tumor progression. Results In this study, we found that miR-1231 was an important tumor suppressor with significantly low expression in NSCLC tissues and cell lines compared with normal controls (all P < 0.001). MiR-1231 expression was significantly associated with tumor size (P = 0.037), lymph node metastasis (P = 0.001) and TNM stages (P = 0.001). Furthermore, the patients with low miR-1231 expression had shorter survival time than those with high miR-1231 expression (log-rank P = 0.010). In addition, miR-1231 was found to serve as an independent prognostic biomarker for the patients. The results of cell experiments indicated that miR-1231 downregulation could markedly promote NSCLC cell proliferation, migration and invasion, while miR-1231 overexpression could markedly inhibit NSCLC cell proliferation, migration and invasion. Conclusion All the data revealed that a downregulated expression of miR-1231 predicts the poor prognosis of NSCLC and promotes the tumor cell proliferation, migration and invasion. Therefore, we considered that miR-1231 may serve as a therapeutic target for NSCLC treatment.

show abstract

Diagnosing Lung Cancers through Examination of Micro-RNA Biomarkers in Blood, Plasma, Serum and Sputum: A Review and Summary of Current Literature

Cited by 59 publications

References 48 publications

Targeting the Mammalian Target of Rapamycin in Lung Cancer

Targeting the Mammalian Target of Rapamycin in Lung Cancer

Design, synthesis and in vitro evaluation of new thiosemicarbazone derivatives as potential anticancer agents

Low miR-1231 expression predicts poor prognosis in non-small cell lung cancer and accelerates cell proliferation, migration and invasion

Contact Info

Product

Resources

About